Differential gene expression (DEG) analysis focusing on a curated list of ~500 genes (including known and emerging viable immunomodulatory targets and other druggable targets of cancer, see Supplementary Data 17) identified 26 significantly upregulated genes (expression FC > 1.2 and adjusted P-value < 0.05) in tumors with low CDKN2A/MTAP expression (lo_lo tumors) (Fig. 6a and Supplementary Data 18). The gene discussed is CDKN2A; the disease is cancer.